Inhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%

Inhibikase Therapeutics, Inc. (NYSE:IKT) shares were down 1.4% on Thursday . The company traded as low as $2.04 and last traded at $2.10. Approximately 27,598 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 126,159 shares. The stock had previously closed at $2.13.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Inhibikase Therapeutics in a research report on Tuesday, March 5th.

Inhibikase Therapeutics Stock Down 2.9 %

The stock has a fifty day moving average of $2.23 and a 200-day moving average of $1.67. The firm has a market capitalization of $13.22 million, a P/E ratio of -0.57 and a beta of 1.19.

Inhibikase Therapeutics (NYSE:IKT) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative return on equity of 107.54% and a negative net margin of 5,886.15%. Sell-side analysts predict that Inhibikase Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Trading of Inhibikase Therapeutics

Hedge funds have recently modified their holdings of the stock. Barclays PLC purchased a new stake in Inhibikase Therapeutics in the 2nd quarter valued at about $41,000. Renaissance Technologies LLC boosted its position in Inhibikase Therapeutics by 17.7% in the second quarter. Renaissance Technologies LLC now owns 221,900 shares of the company’s stock worth $165,000 after purchasing an additional 33,431 shares during the last quarter. Blair William & Co. IL grew its position in shares of Inhibikase Therapeutics by 20.5% during the 1st quarter. Blair William & Co. IL now owns 276,000 shares of the company’s stock valued at $181,000 after acquiring an additional 47,000 shares during the period. Vanguard Group Inc. raised its holdings in shares of Inhibikase Therapeutics by 10.7% in the 1st quarter. Vanguard Group Inc. now owns 530,098 shares of the company’s stock worth $785,000 after purchasing an additional 51,394 shares during the period. Finally, Armistice Capital LLC bought a new stake in shares of Inhibikase Therapeutics in the 1st quarter worth approximately $1,947,000. Institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.